Informe de análisis del tamaño, la participación y las tendencias del mercado mundial de bisturí de rayos gamma: descripción general de la industria y pronóstico hasta 2031

Análisis del mercado de bisturí de rayos gamma

El mercado de la radiocirugía con bisturí de rayos gamma está experimentando un crecimiento significativo, impulsado por los avances tecnológicos, la creciente demanda de tratamientos mínimamente invasivos y la creciente incidencia de trastornos neurológicos. Estos factores, combinados con una mayor conciencia y aceptación de la terapia con bisturí de rayos gamma, están contribuyendo a la expansión constante del mercado. Además, el desarrollo de nuevas aplicaciones para la tecnología de bisturí de rayos gamma, como el tratamiento de metástasis cerebrales y trastornos funcionales, está impulsando aún más el crecimiento del mercado. Además, la creciente disponibilidad de centros de tratamiento con bisturí de rayos gamma en todo el mundo está proporcionando un mayor acceso a esta terapia innovadora, lo que contribuye a la expansión del mercado.

Tamaño del mercado del bisturí de rayos gamma

El tamaño del mercado global de bisturí de rayos gamma se valoró en USD 445,93 millones en 2023 y se proyecta que alcance los USD 658,84 millones para 2031, con una CAGR del 5,0% durante el período de pronóstico de 2024 a 2031. Además de los conocimientos sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera de proyectos, análisis de precios y marco regulatorio.

Tendencias del mercado del bisturí de rayos gamma

“ Concientización a través de conferencias y campañas educativas ”

La creciente conciencia entre los profesionales de la salud y los pacientes sobre los beneficios de la tecnología de bisturí de rayos gamma está impulsando significativamente su adopción en las prácticas médicas. A medida que surgen más resultados clínicos positivos e historias de éxito que muestran la eficacia de los tratamientos con bisturí de rayos gamma para afecciones como tumores cerebrales y malformaciones vasculares, los proveedores de atención médica están cada vez más motivados para integrar estos sistemas avanzados en sus ofertas. Además, las campañas educativas específicas y las conferencias médicas especializadas son fundamentales para difundir el conocimiento sobre las ventajas de la tecnología de bisturí de rayos gamma. Estos eventos a menudo incluyen presentaciones detalladas sobre ensayos clínicos, innovaciones tecnológicas y testimonios de pacientes, que ayudan a desmitificar la tecnología y promover su uso entre los médicos y los pacientes por igual.

Alcance del informe y segmentación del mercado de bisturí de rayos gamma        

Gamma Knife Market Definition

Gamma Knife is a specialized medical device used for the precise and non-invasive treatment of brain tumors, vascular malformations, and other neurological conditions. It employs a targeted array of gamma rays to deliver high doses of radiation to a specific area within the brain, effectively treating abnormal tissues while minimizing damage to surrounding healthy tissue. The device is known for its accuracy and effectiveness in treating conditions such as acoustic neuromas, pituitary tumors, and arteriovenous malformations, making it a valuable tool in stereotactic radiosurgery.

Gamma Knife Market Dynamics

Drivers

• The Rising Prevalence Of Brain Tumours

With approximately 308,102 new cases and 251,329 deaths from brain and central nervous system (CNS) tumours reported globally in 2020, the urgency for effective, non-invasive treatments such as Gamma Knife radiosurgery is increasingly critical. Gamma Knife technology offers a precise and targeted approach to treating these complex conditions, addressing the growing need for advanced therapeutic options that minimize the invasiveness of traditional surgical methods. Such significant demand driven by high incidence and mortality rates underscores the gamma knife's role as a crucial driver in the market, highlighting its importance in advancing non-invasive treatment solutions for neurological disorders.

• Supportive Government Initiatives

The National Cancer Institute (NCI) in the United States has allocated substantial funding to research projects aimed at creating novel cancer medicines, including radiosurgery technologies such as Gamma Knife. Furthermore, national health policies, such as the UK's National Health Service (NHS) funding for cutting-edge cancer therapies, encourage the use of modern technologies. Such policies and funding opportunities are designed to improve patient outcomes and advance the quality of care, contributing significantly to the increased use and market growth of gamma knife systems.

Opportunities

• Innovative Applications for Gamma Knife Radiosurgery

Innovative applications for gamma knife radiosurgery are significantly expanding market opportunities. For instance, recent studies have explored the use of gamma knife radiosurgery in treating refractory epilepsy, particularly in patients with focal seizures that do not respond to medication. According to a study, Gamma Knife Radiosurgery for Mesial Temporal Lobe Epilepsy published in the National Library of Medicine found that gamma knife radiosurgery resulted in seizure freedom or significant reduction in seizures for approximately 50% of patients with epilepsy, highlighting its potential as an effective treatment option. Additionally, research into using gamma knife for certain psychiatric disorders, such as obsessive-compulsive disorder (OCD), has shown promising results in reducing symptoms when traditional therapies are ineffective. Expanding these indications not only enhances treatment options for patients but also drives further growth and adoption of gamma knife technology in the market.

• Growing Adoption of Stereotactic Radiosurgery (SRS)

The growing adoption of stereotactic radiosurgery (SRS) is significantly boosting the gamma knife market as it becomes a preferred treatment for various brain conditions. Stereotactic radiosurgery (SRS) is valued for its non-invasive nature, offering an alternative to traditional surgical methods with minimal recovery time and exceptional precision. For instance, data from the American society for radiation oncology (ASTRO) indicates that SRS is increasingly used for treating brain metastases, with studies showing it to be as effective as whole-brain radiation therapy but with fewer side effects and a shorter recovery period. Shifting trends towards non-invasive, precise treatment options drives the demand for gamma knife systems, underscoring their critical role in modern neurosurgical care.

Restraints/Challenges

• Competition from Alternative Treatments

Competition from alternative treatments presents a significant challenge to the gamma knife market. Advances in radiosurgery techniques, such as cyberknife and linear accelerator-based stereotactic radiosurgery (SRS), offer competitive options for treating brain tumors and other conditions. For instance, the cyberknife system, developed by accuracy, uses image-guided robotic technology to deliver precise radiation therapy, which has been shown to achieve comparable or superior outcomes to gamma knife in certain cases. The growing adoption of such alternative technologies, which often offer enhanced flexibility and fewer constraints compared to gamma knife, underscores the competitive pressures faced by gamma knife systems and thus restricts the market growth.

• High Cost Limiting Market Expansion

High costs associated with gamma knife systems present a significant barrier, with initial purchase prices often reaching multi-million-dollar ranges. The financial burden is compounded by substantial ongoing maintenance and operational expenses, including specialized staff training and technical support. Such unbearable costs can be prohibitive for smaller or resource-constrained facilities, limiting their ability to invest in and adopt gamma knife systems advanced technology. Consequently, the high cost can restrict the widespread availability of gamma knife treatments and hinder the market's overall growth potential.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Gamma Knife Market Scope

The market is segmented on the basis of disease indications, anatomy, end-user and range. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Indications

•  Vascular Disorders
• Brain Metastasis
• Ocular Diseases
• Functional Disorders
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Movement Disorders
• Cancer
• Others

Anatomy

• Head
• Neck
• Others

End User

• Hospitals
• Clinics
• Ambulatory Service Centers

Range

• High-End Gamma Knife
• Medium Gamma Knife
• Low Gamma Knife

Gamma Knife Market Regional Analysis

The market is analyzed and market size insights and trends are provided by disease indications, anatomy, end-user and range.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to several key factors, including escalating healthcare costs which drive investment in advanced medical technologies, a robust focus on research and development related to diabetes management, and a continuous stream of technological advancements. Additionally, the presence of leading industry players and a well-established healthcare infrastructure contribute to North America's market leadership.

Asia-Pacific is projected to experience the fastest growth from 2024 to 2031, driven by a surge in strategic initiatives from major market players seeking to expand their presence in the region. Favourable government initiatives, such as supportive policies and incentives for healthcare innovation, further accelerate market growth. Additionally, increasing healthcare expenditure and rising awareness about diabetes management in rapidly developing economies contribute to the region's expanding market opportunities.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.  

Cuota de mercado del bisturí de rayos gamma

El panorama competitivo del mercado proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y variedad de productos, y el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado.

Los líderes del mercado de bisturí de rayos gamma que operan en el mercado son:

• Elekta (Suecia)
• Varian Medical Systems, Inc. (Estados Unidos)
• Accuray Incorporated (Estados Unidos)
• Vision RT Ltd. (Reino Unido)
• MASEP Medical Science & Technology Development (Shenzhen) Co. (China)
• Nordion (Canadá) Inc. (Canadá)
• Brainlab AG (Alemania)
• CQ Medical (Estados Unidos)
• Ono Sokki Co. Ltd. (India)
• Panacea Medical Technologies Pvt. Ltd. (India)
• Akesis, Inc. (Estados Unidos)
• Fortis Healthcare (India)
• Corewell Health (Estados Unidos)

Últimos avances en el mercado del bisturí de rayos gamma

• En junio de 2024, el Instituto de Investigación Fortis Memorial presentó el Gamma Knife Esprit, lo que marca el debut de este Leksell Gamma Knife en el sur de Asia. Según el hospital, esta tecnología de vanguardia representa una nueva era en el tratamiento no quirúrgico y de alta precisión de los tumores cerebrales, ampliando significativamente las opciones terapéuticas para los tumores cerebrales malignos y benignos, así como para otras anomalías cerebrales.
• En abril de 2024, el Instituto de Neurociencia de AdventHealth se convirtió en el primer centro de Florida Central en utilizar el bisturí de rayos gamma Elekta Esprit para tratar a pacientes con problemas cerebrales. Este sistema de radiocirugía estereotáctica (SRS) de vanguardia proporciona radiación ablativa de alta precisión a áreas específicas del cerebro y, al mismo tiempo, minimiza la exposición del tejido sano circundante.

SKU-10606